Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The company plans to expand their capacity to meet the needs of pharma and biotech industries
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Sputnik M is a new member of the Sputnik vaccines family
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
The fund aims at investing in companies that extends human healthspan
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Subscribe To Our Newsletter & Stay Updated
